

N.B. English translation is for convenience purposes only

The Board of Directors' of NeuroVive Pharmaceutical AB (publ), reg. no. 556595-6538, proposal on authorization for the Board of Directors to resolve on new issues of shares, warrants and/or convertibles (item 8)

The Board of Directors proposes that the Extraordinary General Meeting resolves to authorize the Board of Directors to resolve, on one or more occasions, during the period up until the next Annual General Meeting, on increase of the company's share capital by not more than SEK 690,000, corresponding to an increase by not more than fifteen (15) percent of the company's share capital calculated on full subscription in the Rights issue, by issue of new shares, warrants and/or convertibles, with or without waiving the preferential rights of the shareholders. The authorization replaces the existing authorization for the Board of Directors to resolve on new issues of shares, warrants and/or convertibles, resolved upon at the 2017 Annual General Meeting.

The share issues should be at market subscription price, subject to reservation for a market discount where applicable, and apart from cash, payment may be made in kind or through offset or subject to other terms and conditions.

The purpose of this authorization and the rationale for eventual waiving of shareholders' preferential rights, should be to raise working capital for the company and/or to add new owners of strategic importance to the company.

A valid resolution in accordance with the Board of Directors' proposal according to above requires the approval of shareholders representing at least two thirds of the votes cast and the shares represented at the Extraordinary General Meeting.

Lund in February 2018

NeuroVive Pharmaceutical AB (publ)

The Board of Directors